Ensysce Biosciences (ENSC) Non-Current Assets (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Non-Current Assets of $207461.0 for Q4 2025, down 17.85% year-over-year from $252550.0 in Q4 2024, and down 17.41% quarter-over-quarter from $251194.0 in Q3 2025.
Ensysce Biosciences (ENSC) Non-Current Assets (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Non-Current Assets for 9 consecutive years, with $207461.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Assets fell 17.85% year-over-year to $207461.0; the TTM figure through Dec 2025 stood at $962398.0 (down 23.63% YoY), while the FY2025 annual figure was $207461.0, down 17.85% from the prior year.
- Non-Current Assets eased to $207461.0 in Q4 2025 per ENSC's latest filing, from $251194.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $12.8 million in Q1 2021 and bottomed at -$7.9 million in Q3 2021.
- Historically, Non-Current Assets has averaged $259784.4 across 5 years, with a median of $398383.5 in 2023.
- On a YoY basis, Non-Current Assets climbed as much as 19100.1% in 2021 and fell as far as 159.54% in 2021.
- Ensysce Biosciences' Non-Current Assets stood at $754756.0 in 2021, then slipped by 22.37% to $585883.0 in 2022, then fell by 28.45% to $419217.0 in 2023, then sank by 39.76% to $252550.0 in 2024, then declined by 17.85% to $207461.0 in 2025.
- Business Quant data shows ENSC's Non-Current Assets at $207461.0 in Q4 2025, $251194.0 in Q3 2025, and $292860.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Ensysce Biosciences | 960,039.34 | -3.35 Mn | - | 207,461.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 207,461.00 |
| Sep 30, 2025 | 251,194.00 |
| Jun 30, 2025 | 292,860.00 |
| Mar 31, 2025 | 210,883.00 |
| Dec 31, 2024 | 252,550.00 |
| Sep 30, 2024 | 294,217.00 |
| Jun 30, 2024 | 335,883.00 |
| Mar 31, 2024 | 377,550.00 |
| Dec 31, 2023 | 419,217.00 |
| Sep 30, 2023 | 460,883.00 |
| Jun 30, 2023 | 502,550.00 |
| Mar 31, 2023 | 544,217.00 |
| Dec 31, 2022 | 585,883.00 |
| Sep 30, 2022 | 627,550.00 |
| Jun 30, 2022 | 754,242.00 |
| Mar 31, 2022 | 713,090.00 |
| Dec 31, 2021 | 754,756.00 |
| Sep 30, 2021 | -7.85 Mn |
| Jun 30, 2021 | -7.29 Mn |
| Mar 31, 2021 | 12.75 Mn |